Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium.
Expert Rev Clin Immunol. 2022 Oct;18(10):1015-1022. doi: 10.1080/1744666X.2022.2108791. Epub 2022 Aug 2.
Cannabis is the most widely consumed illicit drug in the world and carries a risk of severe IgE-mediated allergic reactions, requiring appropriate diagnostic management. Currently available diagnostics are still relatively limited and require careful interpretation of results to avoid harmful over- and underdiagnosis.
This review focuses on the most up-to-date understandings of cannabis allergy diagnosis, starting with the main clinical features of the disease and the allergenic characteristics of , and then providing insights into , and diagnostic tests.
At present, the diagnosis of IgE-mediated cannabis allergy is based on a three-step approach that starts with accurate history taking and ends with a confirmation of sensitization to the whole extract and, finally, molecular components. Although much has been discovered since its first description in 1971, the diagnosis of cannabis allergy still has many unmet needs. The lack of commercial standardized and validated extracts and assays makes a harmonized workup of cannabis allergy difficult. Furthermore, the epidemiological characteristics, and clinical implications of sensitization to different molecular components are not yet fully known. Future research will complete the picture and likely result in an individualized and standardized approach.
大麻是世界上使用最广泛的非法药物,有引发严重 IgE 介导过敏反应的风险,需要进行适当的诊断管理。目前可用的诊断方法仍然相对有限,需要仔细解释结果,以避免过度诊断和漏诊。
本文重点介绍大麻过敏诊断的最新认识,首先讨论该疾病的主要临床特征和变应原特性,然后深入了解和 诊断检测。
目前,IgE 介导的大麻过敏诊断基于三步法,首先是准确的病史采集,然后是对全提取物的致敏确认,最后是分子成分。自 1971 年首次描述以来,虽然已经有了很多发现,但大麻过敏的诊断仍有许多未满足的需求。缺乏商业标准化和验证的提取物和 检测试剂盒使得大麻过敏的综合检测变得困难。此外,对不同分子成分致敏的流行病学特征和临床意义尚不完全清楚。未来的研究将完善这一认识,并可能形成个性化和标准化的方法。